转自：北京日报客户端 北京未来医药产业链研究院落户昌平，将充分发挥高端智库与产业服务平台双重作用，产出更多高水平 研究成果，培育更多优质创新项目，为区域乃至全国医药健康产业发展注入新动能。昌平区将以此为契 机，持续优化营商环境，通过政策支持、人才保障等全方位服务，为研究院和各类创新主体在昌发展创 造良好条件，共创产业发展美好未来。 北京未来医药产业链研究院及其理事单位、发起单位相关负责人，区领导柳强、赵仕伟参加。 来源：北京昌平 12月30日，北京未来医药产业链研究院落户昌平区中关村生命科学园。工业和信息化部消费品工业司司 长何亚琼，副司长王孝洋，北京市经济和信息化局副局长顾瑾栩，区委书记、未来科学城党工委书记甘 靖中，区委副书记、区长，未来科学城党工委副书记、管委会主任刘晓东出席。 成立仪式上，何亚琼、顾瑾栩、甘靖中分别致辞。北京未来医药产业链研究院定位于打造医药行业高水 平智库和产业发展服务平台，支持医药产业链上下游协同创新，完善医药产业创新生态，推动医药工业 高质量发展。研究院的成立不仅是落实国务院《医药工业高质量发展行动计划》的重要举措，更是助力 我国医药健康产业发展的关键一环。未来，研究院将开展医药 ...

Core Viewpoint - The establishment of the Hainan Free Trade Port will provide a broader platform for companies, particularly benefiting the research and development of high-end complex formulations, biological drugs, and specialty traditional Chinese medicine products [1] Group 1: Policy Benefits - The policies supporting pharmaceutical companies are comprehensive and systematic, with direct benefits such as exemptions from import tariffs, value-added tax, and consumption tax, significantly reducing operational costs [2] - The Hainan Free Trade Port is creating a complete industrial innovation ecosystem, offering financial rewards for various stages of drug development and clinical research, thus supporting the entire chain from research to manufacturing [2] - The company has already benefited from these policies, with its new drug, Fluorofenone capsules, being included in the list of breakthrough treatment varieties by the National Medical Products Administration [2] Group 2: Innovation and Market Strategy - The company has restructured its R&D system, forming a 92-member team and developing advanced technology platforms, achieving significant progress in new drug development and leading market share in certain products [3] - The company is actively participating in national procurement and has seen growth in exports of raw materials and formulations, indicating a successful market expansion strategy [3] - The company is focusing on internal research and external introduction to enrich and optimize its product pipeline [3] Group 3: Future Development Plans - The company aims to leverage the policy dividends of the Free Trade Port to drive high-quality development, adjusting its business structure to focus on stable pharmaceutical basics, strengthening traditional Chinese medicine, and enhancing medical device development [4] - The company plans to enhance the efficiency of the entire industry chain through lean production management and aims to penetrate global markets, moving beyond domestic competition [5] - The establishment of a cross-border e-commerce platform is intended to facilitate the import of foreign products without registration and promote comprehensive domestic sales, creating a new growth engine [5]